JIANGSU LIANHUAN PHARMACEUTICAL Co.,Ltd.

The company was founded in December 1999 by Yangzhou Pharmaceutical Factory, which was founded in 1958, and successfully landed on the Shanghai main board in March 2003. It currently has 3 high-tech enterprises and 2 “specialized, special and new” enterprises at the provincial level, and has won titles such as “China's Top 100 Chemical Industry Enterprises”, “National Intellectual Property Demonstration Enterprise”, “Jiangsu Excellent Enterprise”, and “National Enterprise for Integrating the Two Technologies”. In 2023, the company was successfully selected to establish a world-class professional leading demonstration enterprise, becoming the first batch of two local state-owned enterprises in the country, two in Jiangsu, and the only local state-owned enterprises in the city to receive this honor. The company's industry is pharmaceutical manufacturing. It is a national high-tech enterprise integrating R&D, production and sales. The company's main business covers the fields of pharmaceutical manufacturing and pharmaceutical distribution. The company's main products include several series of urological drugs, antihistamines, cardiovascular drugs, steroidal hormones, antibiotics, etc., covering various pharmaceutical forms of chemical raw materials, injections, and solid preparations, including the national first-class drug Eprit tablets (Sichuan), the second-class new drug ebastine tablets (Sudi), and felodipine tablets (bicyclidine), danazol capsules and suppositories, metformin glitzide tablets (dosa), lumkinase capsules, sertraline hydrochloride capsules (optimal cyclic determination)), dapoxetine hydrochloride tablets, tadalafil tablets, temozolomide capsules, abiraterone acetate tablets, moxifloxacin hydrochloride tablets, ebastine Products such as oral liquids. The company was successfully selected to create a world-class “specialized, special and new” model enterprise; was recognized by the Jiangsu Provincial Department of Industry and Information Technology as the second batch of provincial star cloud enterprises in 2022, selected and received the highest five-star rating; passed the AA two-tier integrated management system certification; rated by the Jiangsu Pharmaceutical Quality Management Association as an excellent enterprise for the 2023 Jiangsu Pharmaceutical Industry Quality Management (QC) Group Activities; the company is a specialized and innovative small and medium-sized enterprise in Jiangsu Province, a demonstration enterprise for industrial Internet development (benchmark factory category), rated as “AAA” by Oriental Android (Beijing) International Credit Assessment Center “Credit Enterprise”, won the honor of “National Intellectual Property Demonstration Enterprise”, etc.